Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

accord healthcare b.v. - vinorelbintartrat - konsentrat til infusjonsvæske, oppløsning - 10 mg/ ml

Եվրոպական Միություն - Նորվեգերեն - EMA (European Medicines Agency)

accord healthcare s.l.u. - posakonazol - mycoses - antimykotika for systemisk bruk - posaconazole accord is indicated for use in the treatment of the following fungal infections in adults:invasive aspergillosis;fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refraktivitet er definert som progresjon av infeksjon eller unnlatelse av å forbedre etter minimum 7 dager før terapeutiske doser av effektive soppdrepende behandling. posaconazole accord er også indisert for profylakse av invasive soppinfeksjoner i følgende pasienter: pasienter som mottar syndenes-induksjon kjemoterapi for akutt myelogen leukemi (aml) eller myelodysplastic syndromer (mds) forventes å resultere i langvarig neutropenia og som har høy risiko for å utvikle invasive soppinfeksjoner;blodkreft stamcelletransplantasjon (hsct) mottakere som er under høy-dose immunsuppressiv terapi for graft versus host disease og som har høy risiko for å utvikle invasive soppinfeksjoner.

Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

accord healthcare b.v. - solifenacinsuksinat - tablett, filmdrasjert - 5 mg

Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

accord healthcare b.v. - solifenacinsuksinat - tablett, filmdrasjert - 10 mg

Եվրոպական Միություն - Նորվեգերեն - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroksaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antithrombotic agents - forebygging av venøs tromboembolisme (vte) hos voksne pasienter som gjennomgår valgfri hofte- eller kneutskifting. behandling av dyp venetrombose (dvt) og lungeemboli (pe), og forebygging av tilbakevendende dvt og pe i voksne. (see section 4. 4 for haemodynamically unstable pe patients. behandling av dyp venetrombose (dvt) og lungeemboli (pe), og forebygging av tilbakevendende dvt og pe i voksne. (see section 4. 4 for haemodynamically ustabil pe pasienter). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. behandling av dyp venetrombose (dvt) og lungeemboli (pe), og forebygging av tilbakevendende dvt og pe i voksne. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 og 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. behandling av dyp venetrombose (dvt) og lungeemboli (pe), og forebygging av tilbakevendende dvt og pe i voksne. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

accord healthcare b.v. - aciklovirnatrium - konsentrat til infusjonsvæske, oppløsning - 25 mg/ ml

Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

accord healthcare b.v. - atosibanacetat - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 6.75 mg/0.9 ml

Եվրոպական Միություն - Նորվեգերեն - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, type 2 - legemidler som brukes i diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

accord healthcare b.v. - vildagliptin - tablett - 50 mg

Եվրոպական Միություն - Նորվեգերեն - EMA (European Medicines Agency)

accord healthcare s.l.u. - dimetylfumarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunsuppressive - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).